JPRN-jRCT1031210554
Recruiting
未知
A study on the efficacy of the loss of response to jaw thrust as a clinical test to assess adequate depth of anesthesia using remimazolam besylate and the dose required for the loss of response.
Okuda Yasuhisa0 sites70 target enrollmentJanuary 17, 2022
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Okuda Yasuhisa
- Enrollment
- 70
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patients with written consent to participate in this study.
- •2\) Patients aged between 20 and 65 at the time of consent.
- •3\) American Society of Anesthesiologists (ASA) Grade I or II patients.
- •4\) Patients whose surgical purpose is other than heart surgery.
Exclusion Criteria
- •1\) Patients undergoing emergency surgery.
- •2\) Patients who may be pregnant.
- •3\) Patients who are expected to have difficulty airway management or intubation.
- •4\) BMI 28 and above.
- •5\) Patients who have high risk of aspiration.
- •6\) Patients with liver dysfunction: Child\-pugh classification B or higher.
- •7\) Patients with contraindications to propofol or remimazolam.
- •8\) Patients with a history of alcoholism or drug abuse.
- •9\) Patients who regularly use sedatives.
- •10\) Patients with a history of cervical spine / cervical cord disease.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study of the effectiveness of the response and interferon combination therapy for ribavirin monotherapy for chronic hepatitis CChronic hepatitis CJPRN-UMIN000017560Hokkaido University30
Not yet recruiting
Phase 3
Evaluation of the response and adverse effects of total neoadjuvant therapy (TNT) of advanced localized rectal cancerC18.7Rectal cancer.Malignant neoplasm of sigmoid colonIRCT20120215009014N431Hamedan University of Medical Sciences25
Active, not recruiting
Phase 1
Study about the response to the administration of a third dose of mRNA-1273 vaccine (COVID19 vaccine Moderna) in renal transplants with immunological failure initial to vaccinatioCOVID19 vaccine in kidney transplant patientsMedDRA version: 23.1Level: LLTClassification code 10084464Term: COVID-19 immunizationSystem Organ Class: 100000004865MedDRA version: 23.1Level: LLTClassification code 10084465Term: COVID-19 vaccinationSystem Organ Class: 100000004865Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2021-002356-37-ESFundació Clinic per a la Recerca Biomèdica (FCRB)80
Completed
Not Applicable
A study to evaluate the dose-response effect of tolvaptan 7.5mg or 15mg in HF patients who undergo cartdiac angiographyHeart FailureJPRN-UMIN000009924Showa University Northern Hospital100
Completed
Not Applicable
The Effect of the Prevention Education Program on Performance of Parents.IRCT2017053034226N1Deputy of Research and Technology of Arak University of Medical Sciences150